Every HIV medication you take today — Biktarvy, Descovy, cabotegravir, all of it — exists because thousands of people living with HIV volunteered for clinical trials. Trials are how medicine advances. They are also an opportunity: access to new treatments before they're widely available, free expert medical monitoring, and in many cases meaningful compensation for your time.
But ClinicalTrials.gov — the federal database where all trials are registered — was designed by scientists for scientists. The language is dense, the search tools are clunky, and most people who land on it leave more confused than when they arrived. This guide is the decoder ring.
Bottom line upfront: HIV clinical trials range from simple blood draw studies to complex multi-year treatment research. Most currently recruiting HIV trials are outpatient, do not require you to stop your current medications, and offer at minimum travel reimbursement — and many pay significantly more. You can ask questions, take time to decide, and leave at any point. Your rights as a participant are protected by federal law.
What a clinical trial actually is
A clinical trial is a research study in which people volunteer to help answer a specific medical question. Not all clinical trials test new drugs. HIV trials in 2026 include studies of new treatment regimens, cure strategies, prevention approaches, wellness interventions, behavioral support, and care delivery models. Some require nothing more than answering questions. Others involve new medications, procedures, or lab work.
Every trial is governed by a protocol — a detailed plan spelling out exactly what will happen, to whom, and why. Every trial must be reviewed and approved by an Institutional Review Board (IRB) — an independent ethics committee that evaluates whether the trial is safe, ethical, and scientifically sound before a single participant is enrolled.[2] Every trial must be registered on ClinicalTrials.gov, which is why the database exists.[1]
Participation is always voluntary. You can ask questions before deciding. You can change your mind after enrolling. You cannot be penalized for withdrawing. These are not suggestions — they are federal requirements.[3]
The jargon, decoded
Clinical trial documents are full of terms that sound intimidating but aren't. Here are the ones you'll encounter most often:
Clinical trial phases — what they actually mean
Drugs move through phases before approval.[5] Most people living with HIV will encounter Phase II, III, or IV trials — the phases where safety has already been established and the research focuses on effectiveness, dosing, and long-term outcomes.
The 5 types of HIV clinical trials
HIV trials are not all about cure research or experimental drugs. The range is much broader — and knowing what's out there helps you find what actually fits your situation.
How to actually find HIV trials
ClinicalTrials.gov is the authoritative source — but you need to know how to use it. Here's the step-by-step approach that cuts through the noise.
Other ways to find trials
Ask your HIV provider. This is the most underused pathway. Your HIV doctor or the clinic's research coordinator often knows about trials actively recruiting in your area — including ones not easy to find on ClinicalTrials.gov. Ask directly: "Are there any clinical trials you'd recommend I look into?"
Your Ryan White clinic. Many Ryan White-funded HIV clinics are affiliated with research institutions and actively recruit participants. Ask your case manager or clinic coordinator.
Treatment Action Group (TAG). TAG maintains a curated, plain-language list of HIV cure-related clinical trials at treatmentactiongroup.org/cure/trials — updated monthly.[7]
HIVinfo (NIH). The NIH's HIV information service at hivinfo.nih.gov has a clinical trials page and a helpline (1-800-448-0440) where health information specialists can help you find and understand studies.[8]
ResearchMatch. A free NIH-supported tool at researchmatch.org that connects volunteers with researchers — you create a profile and get matched to relevant studies.[9]
Paid vs. unpaid: the honest breakdown
About 60% of U.S. clinical trials offer some form of compensation to participants. For HIV trials specifically — which are mostly outpatient, Phase II–IV, and focused on people already living with and managing HIV — the compensation picture looks like this:
| Trial type | Typical compensation | What it covers |
|---|---|---|
| Behavioral / observational Surveys, interviews, app-based |
$25–$150 per visit | Time stipend. Usually gift cards, prepaid debit, or check. Minimal time commitment. |
| Comorbidity / wellness studies Blood draws, imaging, questionnaires |
$50–$300 per visit, $200–$800 total | Time + travel. Outpatient. Often parking validated at clinic. |
| Phase II–III ART regimen trials Drug effectiveness studies |
$75–$200 per visit, $500–$2,000+ total | Time + travel + sometimes study medication provided free. Multiple visits over months or years. |
| Cure / remission research bNAbs, CAR-T, ATI studies |
$100–$500+ per visit, $2,000–$8,000+ total | Higher compensation for higher time commitment and risk. Frequent monitoring visits. Some require travel to academic medical centers. |
| Phase I / first-in-human Rarely involves current PLHIV |
$1,000–$10,000+ | Highest compensation for highest unknown risk. Most HIV Phase I trials enroll healthy HIV-negative volunteers or HIV-positive people with specific treatment histories. |
Tax note: Clinical trial compensation is taxable income. If you receive $600 or more from a single study in a calendar year, the research institution is required to report it to the IRS and issue you a 1099.[10] Keep track of what you receive. This doesn't mean you shouldn't participate — it just means you should be aware of it.
What compensation is and isn't
Compensation in clinical trials is legally required to be fair payment for time and effort — not an inducement to take risks you wouldn't otherwise take.[11] An IRB reviews every compensation structure before the trial begins to make sure it's not so high that it pressures people into participating against their better judgment. If you find yourself feeling like the money is the only reason you'd do something, that's worth sitting with.
Most HIV trials also provide the study medication free of charge, free lab work as part of the protocol, and free monitoring by expert research clinicians — which has real value independent of any cash compensation.
You should never have to pay to participate in a legitimate clinical trial. If a study asks you to pay for the experimental treatment, that is a major red flag. Legitimate trials do not charge participants.
How to enroll: step by step
Questions to ask before you sign
- What exactly will happen to me at each visit? How long, how often, what procedures?
- Will I need to change my current HIV medications? If yes — why, and what happens if the change causes problems?
- What are the known risks? What are the things they're still uncertain about?
- What happens if I experience a side effect or adverse event? Who do I call? Who pays for treatment?
- What is the compensation structure? When and how will I be paid?
- Can I continue seeing my regular HIV provider? Or does this replace my standard care?
- What happens to my care if I withdraw? Will I be able to get back on my current regimen?
- When will results be available, and how will I find out?
- Is there an ATI (treatment interruption) required? If yes — see the next section before proceeding.
Analytical Treatment Interruptions — read this before agreeing
Some HIV cure research trials — particularly studies testing broadly neutralizing antibodies, immune-based therapies, and latency reversal agents — require participants to temporarily stop taking their ART. This is called an Analytical Treatment Interruption, or ATI.[14]
The purpose of an ATI is scientific: researchers need to see whether an experimental intervention can control HIV replication in the absence of daily medication. You can't measure that while someone is on ART, because the drug is doing the work.
What this means practically: during an ATI, your viral load will likely rebound. HIV will become detectable in your blood. Your CD4 count may decrease. The research team will monitor you very closely during this period — typically with labs every one to two weeks — and will restart your ART if certain thresholds are crossed.
ATIs carry real risks. Viral rebound can cause acute retroviral syndrome — flu-like symptoms including fever, fatigue, swollen lymph nodes. Elevated viral load means HIV is transmissible again, even if you were previously U=U. CD4 count decreases can, in rare cases, allow opportunistic infections if the interruption goes on too long. The vast majority of ATIs in well-designed trials are time-limited and heavily monitored, with clear stopping rules — but these risks are real and deserve clear-eyed consideration before you say yes.
Questions to ask specifically about ATI studies: How long is the interruption expected to last? What are the viral load and CD4 thresholds that will trigger restarting ART? Will my partner(s) be informed, and how should I handle disclosure? What are the exact risks to my health? What monitoring will occur during the interruption? Has this protocol been done before, and what were the outcomes?
ATI studies can contribute enormously to cure science — and some participants find the contribution deeply meaningful. But they require a higher level of informed consent than most other HIV trials, and you should take your time before agreeing to one.
Your rights as a trial participant
Federal regulations govern the rights of clinical trial participants.[12] These are not suggestions — they are legal requirements that every legitimate trial must follow.
- You must receive a thorough explanation of the study, in plain language, before you decide whether to participate.
- You must be told about all known risks and benefits — and about areas of uncertainty.
- You have the right to ask questions at any point, and to receive honest answers.
- You can take time to decide. No legitimate study will pressure you to sign on the spot.
- You can withdraw from a study at any time, for any reason, without penalty or impact on your standard HIV care.
- If you withdraw, you are entitled to receive standard-of-care treatment — the trial team cannot withhold your ART or other medications because you left the study.
- Your medical information is confidential. The research team cannot share your HIV status or other personal health information without your written consent.
- If new safety information emerges during the study that might affect your decision to remain enrolled, you must be informed.
- You have the right to know the study results when they are published.
- You must be informed of any compensation available for injuries that occur as a result of participation — and what the process is for accessing that compensation.
If something feels wrong: Every trial has an IRB contact — an independent ethics board separate from the research team. If you feel your rights are being violated, your safety is not being monitored appropriately, or you're experiencing pressure you don't know how to handle, you can contact the IRB directly. The IRB contact information should be on your informed consent document. You can also contact the FDA's Office of Good Clinical Practice or the Office for Human Research Protections (OHRP) at HHS.[13]
Florida research sites
Florida has a substantial HIV clinical research infrastructure, concentrated in its major metro areas. If you're in Florida and interested in trial participation, these are the primary institutions with active HIV research programs:
To find Florida trials specifically: Use the ClinicalTrials.gov search above and filter by State → Florida. Alternatively, call your Ryan White clinic and ask if they are affiliated with any research programs — many are, and being an established patient often makes you easier to enroll. Your HIV provider may also be a principal investigator on a study you never knew about.
Why community participation matters
HIV clinical research has a diversity problem. Historically, trial populations have been predominantly white, male, and from major metropolitan areas — which means the data on how treatments work in Black and Latino communities, in women, in people over 60, and in rural populations is thinner than it should be. The treatments that emerge from trials need to work for everyone — which means everyone needs to be represented in the research that creates them.
Participating in HIV clinical research is one of the most concrete contributions any PLHIV can make to the epidemic response. Not everyone will qualify, not everyone will be able to commit the time, and not every trial is right for every person. But if you can do it and a trial fits your situation, the contribution is real and lasting.
References & Sources
- National Library of Medicine. "ClinicalTrials.gov." The federal registry and results database of publicly and privately supported clinical studies. clinicaltrials.gov ↩
- U.S. Food and Drug Administration (FDA). "Institutional Review Boards (IRBs) and Protection of Human Subjects in Clinical Trials." fda.gov — IRBs and Protection of Human Subjects ↩
- Office for Human Research Protections (OHRP), U.S. Department of Health and Human Services. "45 CFR 46 — Protection of Human Subjects (the Common Rule)." hhs.gov/ohrp — 45 CFR 46 Common Rule ↩
- ClinicalTrials.gov. "About NCT Numbers." NCT identifiers are assigned to each registered study. clinicaltrials.gov — Protocol Registration ↩
- FDA. "Step 3: Clinical Research." Description of Phase 1–4 clinical trials. fda.gov — Step 3: Clinical Research ↩
- Gilead Sciences. "PURPOSE Studies: Lenacapavir for HIV Prevention." Overview of the PURPOSE 1 and PURPOSE 2 pivotal trials of twice-yearly lenacapavir for PrEP. gilead.com/purpose ↩
- Treatment Action Group (TAG). "Research Toward a Cure Trials." Curated, plain-language list of HIV cure trials updated regularly. treatmentactiongroup.org/cure/trials ↩
- National Institutes of Health (NIH). "HIVinfo — HIV/AIDS Information Service." HIV clinical trials information and helpline (1-800-448-0440). hivinfo.nih.gov ↩
- Vanderbilt University Medical Center / NIH. "ResearchMatch." Free NIH-supported registry connecting volunteers with researchers. researchmatch.org ↩
- Internal Revenue Service (IRS). "Instructions for Forms 1099-MISC and 1099-NEC." $600 threshold for reportable payments (Box 3 — Other income). irs.gov — Instructions for 1099-MISC / 1099-NEC ↩
- Office for Human Research Protections (OHRP). "Guidance on Payment and Reimbursement to Research Subjects." hhs.gov/ohrp — Payment and Reimbursement Guidance ↩
- Office for Human Research Protections (OHRP). "45 CFR 46, Subpart A — Basic HHS Policy for Protection of Human Research Subjects (informed consent, right to withdraw, IRB oversight)." hhs.gov/ohrp — 45 CFR 46 Subpart A ↩
- U.S. Department of Health and Human Services. "Office for Human Research Protections (OHRP)." Complaints about research involving human subjects. hhs.gov/ohrp — Compliance and Reporting ↩
- National Institute of Allergy and Infectious Diseases (NIAID). "HIV Cure Research: Analytical Treatment Interruptions." Overview of ATIs in HIV cure trials, their scientific purpose, and safety considerations. niaid.nih.gov — HIV Cure Research ↩